Understand the source comparison
Peptides for Mold Illness Research: Mechanism Comparison
VIP (Vasoactive Intestinal Peptide) Neuropeptide restoration, cytokine modulation TNF-alpha, IL-6 inhibition; IL-10 upregulation; VIP receptor signaling Intranasal 50–200 mcg/day (divided doses) VCS normalization, shortness of breath resolution, serum VIP >23
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- VIP (Vasoactive Intestinal Peptide)
- Neuropeptide restoration, cytokine modulation
- TNF-alpha, IL-6 inhibition; IL-10 upregulation; VIP receptor signaling
- Intranasal
- 50–200 mcg/day (divided doses)
- VCS normalization, shortness of breath resolution, serum VIP >23 pg/mL
- Most direct intervention for VIP deficiency in CIRS; short half-life requires frequent dosing
- Thymosin Alpha-1
- T-regulatory cell enhancement, immune tolerance restoration
- Foxp3 upregulation, TGF-beta1 reduction, Treg population expansion
- Subcutaneous injection
- 1.6–3.2 mg twice weekly
- C4a, TGF-beta1, MMP-9 normalization; Treg population increase
- Best evidence for immune system retraining; cumulative effect requires 12–16 weeks minimum
- LL-37 (Cathelicidin)
- Antimicrobial defense, LPS neutralization, innate immune modulation
- TLR-4 inhibition, LPS binding, epithelial barrier repair
- 2–5 mg daily
- Gut permeability reduction, LPS-induced inflammation suppression
- Addresses co-occurring bacterial endotoxin exposure common in water-damaged buildings
- BPC-157
- Gut barrier restoration, anti-inflammatory signaling
- Mucosal healing, pro-inflammatory cytokine suppression, angiogenesis
- Subcutaneous or oral
- 250–500 mcg once or twice daily
- GI symptom resolution, epithelial barrier integrity restoration
- Adjunctive therapy for gut-dominant CIRS cases; limited CIRS-specific research but strong mechanistic rationale